↓ Skip to main content

First-in-human study to assess the safety, tolerability, pharmacokinetics and immunogenicity of DS002, an anti-nerve growth factor monoclonal antibody

Overview of attention for article published in Frontiers in Pharmacology, December 2022
Altmetric Badge

Mentioned by

twitter
1 X user

Citations

dimensions_citation
3 Dimensions

Readers on

mendeley
8 Mendeley